Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2962073rdf:typepubmed:Citationlld:pubmed
pubmed-article:2962073lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2962073lifeskim:mentionsumls-concept:C0004096lld:lifeskim
pubmed-article:2962073lifeskim:mentionsumls-concept:C0242896lld:lifeskim
pubmed-article:2962073lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:2962073pubmed:dateCreated1988-1-25lld:pubmed
pubmed-article:2962073pubmed:abstractTextAlthough 'chronic asthma' is a loosely defined disease, it may be equated approximately with non-allergic or 'intrinsic' asthma arising in adult life. In patients with this condition anticholinergic agents, particularly ipratropium bromide, have been shown to have a useful and rather prolonged bronchodilator action. This bronchodilatation approaches that achieved by therapeutic doses of Beta-agonists and is not associated with undesirable effects such as difficulty in sputum clearance. In conclusion anticholinergic agents are a safe and useful adjunct to other bronchodilators in patients with chronic asthma.lld:pubmed
pubmed-article:2962073pubmed:languageenglld:pubmed
pubmed-article:2962073pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2962073pubmed:citationSubsetIMlld:pubmed
pubmed-article:2962073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2962073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2962073pubmed:statusMEDLINElld:pubmed
pubmed-article:2962073pubmed:issn0032-5473lld:pubmed
pubmed-article:2962073pubmed:authorpubmed-author:SterlingG MGMlld:pubmed
pubmed-article:2962073pubmed:issnTypePrintlld:pubmed
pubmed-article:2962073pubmed:volume63 Suppl 1lld:pubmed
pubmed-article:2962073pubmed:ownerNLMlld:pubmed
pubmed-article:2962073pubmed:authorsCompleteYlld:pubmed
pubmed-article:2962073pubmed:pagination41-6lld:pubmed
pubmed-article:2962073pubmed:dateRevised2009-10-22lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:meshHeadingpubmed-meshheading:2962073-...lld:pubmed
pubmed-article:2962073pubmed:year1987lld:pubmed
pubmed-article:2962073pubmed:articleTitleAnticholinergic therapy in chronic asthma.lld:pubmed
pubmed-article:2962073pubmed:affiliationGeneral Hospital, Southampton, UK.lld:pubmed
pubmed-article:2962073pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2962073pubmed:publicationTypeReviewlld:pubmed